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part series, this article focuses on re-
form options related to the scope of
the legislation and the GMO definition.
A wide range of stakeholders have
recently called for reform of the legal
framework for GMOs in the EUi [1–4].
One argument is that the implementa-
tion of the EU GMO law may lean too
much towards precaution at the cost
of stalling innovation [4,5]. There is
also concern that the EU could forego
potential benefits of technological in-
novations not only in transgenesis but
also in gene editing; as a judgment of
the Court of Justice of the European
Union (CJEU) on the scope of the muta-
genesis exemption in the GMO legisla-
tion (case C-528/16ii) implies, the prod-
ucts of targeted mutagenesis are also
subject to the GMO legislative provi-
sions [6,7]. The nondetectability of
most products of gene editing hasalso made enforcement following the
CJEU case C-528/16ii difficult, if not
impossibleiii.Molecularbreeding technologies, suchas
transgenesis and targeted mutagenesis,
have the potential to contribute to sus-
tainable agriculture and food security by
increasing agricultural yields, reducing
pesticide use [8,9], and increasing the
nutritional value of food and feed crops
[10]. In Box 1, we present a number of
potentially beneficial applications. The
use of molecular tools results in products
facing regulatory environments that differ
by country,withprocedures that aremore
demanding in some countries than in
others. While some stakeholders recog-
nize stringent regulatory procedures as a
means to prevent harm, others empha-
size that overly strict regulations may act
as a disproportionate threshold with the
potential to hinder innovation [11]. Regu-
latory procedures for the testing and
commercial approval ofGMOs are partic-
ularly lengthy and costly in the EU, as
compared to the USA, Canada, and
many other countries [12,13]. By contrast,
authorization procedures provide a
means to transfer information regarding
the potential harm of these organisms
from businesses to regulators, potentially
closing the information gap between
these two. If properly applied, the regula-
tory procedure is viewed as an enabler for
more scientifically robust and socially
acceptable public policies [14]. At the
same time, applications for cultivation
authorization ofGMcrops aswell as fund-
ing for GMO research have been
decreasing in the EU [15], which has
been connected to a reduction in the
overall levelof innovation [16].These facts
provide a strong indication that the cur-
rent regulatory framework is no longer
fit for purpose.
With a focus on GM crops, we present
details for a reform based on a rigorous
application of a risk-based approach. InTrends in Bthis article, which is the first in a series
of three, we briefly describe the current
EU regulatory framework and discuss re-
form options related to the scope of the
legislation and the GMO definition (Fig-
ure 1). The subsequent two articles
discuss reform options in terms of risk
assessment and risk management as
well as post-authorization requirements.The Current EU GMO Legislation
The regulation ofGMOsgainedattention
in the EU in the late 1980s. The first Coun-
cil Directive 90/220/EEC covered their
deliberate release into the environment
and market introduction. Following a
number of food crises and the require-
ment to realign withWorld TradeOrgani-
zation law, several member states asked
for a revision of the approval process
and requirements for placing GMOs on
the market by the end of the 1990s. In
response to this, a new legal framework
[inter aliaDirective 2001/18/EC, Directive
2004/35/EC, Regulations (EC) No 178/
2002, (EC) No 1829/2003, (EC) No
1830/2003, and Recommendations for
Coexistence] additionally introduced
labelling and traceability requirements,
a liability framework for adventitiouspres-
ence, a centralized authorization proced-
ure for GMOs, and coexistence recom-
mendations. Risk assessment and risk
management are largely harmonized at
the EU level. However, in line with the re-
quirements of the treaties governing the
EU, a member state may provisionally
restrict or prohibit the use and/or sale of
a particular GMO under the safeguard
clause of Directive 2001/18/EC if new
findings indicating potential environ-
mental or health risks of the organism
appear. Since 2015, member states may
additionally restrict orprohibit the cultiva-
tion of GM crops on their territory based
on other than risk-related criteria. GMOs
obtained by techniques listed in Annex
1B of Directive 2001/18/EC are exempt
from the specific risk assessment, authori-
zation, labelling, and traceabilityiotechnology, March 2020, Vol. 38, No. 3 231
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Figure 1. Reform Options of the Legislative Framework for Genetically Modified Organisms in
the European Union, Concerning the Scope and Definitions. Problematic issues with the
regulatory framework are identified in the yellow boxes; suggested potential solutions are
identified in the green boxes.
Trends in Biotechnologyprocedures. This includes mutagenesis
techniques that were in use before the
Directive entered into force in 2001 but
not newer forms of mutagenesis, accord-
ing to the CJEU decision in case C-528/
16ii.
Reforming the Scope and
Definitions
Assessment by Product, Not Process
Three decades of research on GMOs
have shown that potential risks associ-232 Trends in Biotechnology, March 2020, Vol. 38,ated with a new variety are related to
the phenotypic traits of the plant and
its derived products and not the tech-
nique that was used for breeding [17].
This is in stark contrast to the emphasis
on process as a trigger for the applica-
bility of the GMO legislation in the EU.
We propose to amend this framework
to move away from process-based trig-
gers for regulatory oversight and put a
stronger emphasis on the product.
One measure could be to establish aNo. 3definition of GMO that is more in line
with the definition of a Living Modified
Organism (LMO) in the Cartagena Pro-
tocol on Biosafety (CPB) to the Conven-
tion on Biological Diversity, which stip-
ulates that an LMO is ‘any living
organism that possesses a novel combi-
nation of genetic material obtained
through the use of modern biotech-
nology.’ This is in line with the view ex-
pressed by some EU member states
before the CJEU judgment on the
mutagenesis exemption [18]. Another
alternative would be to amend Annex
1B of Directive 2001/18/EC, as pro-
posed by the Dutch governmentiv, by
which the exemption from the provi-
sions of the Directive would apply to or-
ganisms not containing sequences
foreign to the organisms’ gene pool
and/or recombinant nucleic acids. This
would imply that products harboring
only point mutations and no foreign
DNA would be exempt from harmo-
nized regulation [1]. The CJEU ruling
in Case C-528/16ii, however, also stipu-
lated that exempted products of muta-
genesis can be regulated at a national
level, so this approach would carry the
risk of further fragmentation of the EU
internal market. Another possibility
would be to introduce a stratified
approach similar to that proposed by
the Norwegian Biotechnology Advisory
Board, according to which, regulatory
requirements are adjusted based on
the type of genetic change [2]. More
generally, we propose that products
that are identical to those that can be
developed using any conventional
breeding technique, and/or may (to a
reasonable degree of probability) occur
without human intervention, should not
be subject to the provisions of the EU
GMO legislation as they currently
stand. We believe it is reasonable
from a risk perspective that identical
products are subject to similar regula-
tory procedures. This would also be in
line with the regulatory approach taken
Box 1. Transgenesis and Gene Editing in Plant Research and Breeding
Plant breeders depend on genetic variation for the development of new desirable traits in agri-
cultural crops. To increase genetic variability in a particular species, breeders have for a long
time used wide crosses, hybridization, randomly-induced mutagenesis, and other techniques.
Transgenesis and gene editing has opened up new horizons as the genetic variation available
for breeding has become much larger.
The use of the CRISPR–Cas systems and other gene editing techniques to develop crops with
new desirable traits is a very dynamic field of research. According to a recent review, around
100 market-relevant applications of gene editing in 28 different crop species have already
been documented in scientific publications [20], and this number is increasing rapidly. Many
of the applications involve resistance against fungal, bacterial, and viral diseases in crops,
such as rice, wheat, maize, banana, and cassava. Disease resistance is a valuable trait to reduce
crop losses and chemical pesticide sprays. Further, crops more tolerant to soil salinity, drought,
and other climate stresses have been developed. Market-relevant applications also include
crops with improved food and feed quality traits, such as wheat with reduced gluten content,
vegetables with increased vitamin levels, and oil crops with improved oil composition and
decrease of antinutritional compounds [10]. Many other gene editing applications are in the
research pipeline and could help to make agriculture more sustainable and climate smart
[21]. Under the current GMO legislation, such applications can hardly be developed and field
tested in the EU, let alone commercially used.
Trends in Biotechnologyin many jurisdictions on the American
continents and elsewhere [19].Designated EU Authority for
Determination of GMO Status
The recent CJEU ruling in case C-528/
16ii provides an indication as to how
the scope of Directive 2001/18/EC
should be interpreted in relation to
mutagenesis. However, many ques-
tions regarding what exactly is covered
by the EU GMO laws remain, in partic-
ular, for techniques that are not a form
of mutagenesis. In order to cope with
the fast-moving pace of innovation, so-
cietal developments, and the need for
predictability of legal systems, a desig-
nated expert committee could be en-
trusted with a mandate to issue
nonbinding recommendations on the
various legal terminologies and to
decide whether specific genetically
altered organisms should be within the
scope. This approach would be similar
to the ‘Am I regulated?’ approach of
the United States Department of Agri-
culturev, which has offered nonbinding
advice to applicants since 2011. The or-
ganization and mandate of such adesignated expert committee needs
to be designed in accordance with the
requirements of EU law for the estab-
lishment of such bodies (as witnessed,
e.g., by the Meroni doctrine) and has
to make certain that the institutional
balance within the EU is maintained.
The composition of this expert group
should be framed by EU law to ensure
that the correct legal and scientific
expertise is present and EU law is
observed.Conditions of Recital 17 of Directive
2001/18/EC
Recital 17 of Directive 2001/18/EC stip-
ulates that: ‘This Directive should not
apply to organisms obtained through
certain techniques of genetic modifica-
tion which have conventionally been
used in a number of applications and
have a long safety record.’ The exemp-
tion currently applies to conventional,
randomly-induced mutagenesis, how-
ever, it is not specified exactly what
the requirement of a long safety record
entails. The inclusion of Recital 17 dem-
onstrates an early intention to shape a
GMO regulatory framework that wouldTrends in Bevolve and take experience into ac-
count. We suggest implementation of
a product-oriented approach when in-
terpreting the requirement of a long
safety record in Recital 17. This would
resemble the practice of safety assess-
ments, as safety assessments measure
product-related features. It is not the
mutagenesis technique itself that has a
long safety record; it is the products
that were introduced to the market or
released into the environment after
additional breeding and variety regis-
tration. Article 7 of Directive 2001/18/
EC provides the possibility for differen-
tiated (simplified) procedures for risk
assessment and management when-
ever sufficient experience with a partic-
ular GMO has been gained [3]. Howev-
er, to date, Article 7 has never been
used, which underlines that the original
intention of an evolving regulatory
practice is not being followed and that
Directive 2001/18 is interpreted in a
static way. This makes a reform of the
Directive particularly important.
In the next article, we continue discus-
sing various details that may be
reformed within the risk assessment
and risk management procedures.
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Science & SocietyStacked Bt Proteins
Pose No New Risks
to Nontarget
Arthropods
Jo¨rg Romeis1,*
and Michael Meissle1
Concerns have been raised that multi-
ple insecticidal proteins produced by
genetically engineered (GE) crops
may interact unexpectedly and pose
new threats to biodiversity and
nontarget organisms. We reviewed
the literature to assess whether this
concern is justified and whether the
current regulatory framework needs to
be adapted to address this concern.
GE crops producing insecticidal pro-
teins from Bacillus thuringiensis (Bt)
have been grown on millions of hect-
ares worldwide for more than 20 years.
Before the cultivation of any new GE
plant, potential adverse effects on
valued nontarget organisms are as-
sessed. This nontarget risk assessment
follows a tiered approach in which
testing begins with laboratory studies
under highly controlled conditions.
High concentrations of the purified
insecticidal proteins or GE plant tissue
are fed to representative test species
with the aim of creating worst-case
exposure conditions. If adverse effects
are detected or if unacceptable
